|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02367 GIANT BIOGENE
Nominal 
55.950 0.000 (0.000%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 3,524,143 | 49.047% | 2,364,445 | 1,552,486 | 1,190,479 | 956,702 |
| Cost of Sales | (577,006) | 56.283% | (369,205) | (198,149) | (183,410) | (159,990) |
| Gross Profit | 2,947,137 | 47.708% | 1,995,240 | 1,354,337 | 1,007,069 | 796,712 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 700 | -- | (614) | (326) | 2,479 | (1,024) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 1,745,089 | 48.172% | 1,177,749 | 972,917 | 973,242 | 676,996 | |
| Taxation | (296,887) | 68.530% | (176,163) | (144,785) | (146,757) | (101,816) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 3,551 | 708.884% | 439 | 0 | (35) | (22,920) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 1,451,753 | 44.882% | 1,002,025 | 828,132 | 826,450 | 552,260 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (47,379) | 260.626% | (13,138) | (9,408) | (9,882) | (16,181) |
| Depreciation & Amortisation | 34,175 | 23.697% | 27,628 | 24,210 | 22,291 | 17,882 |
| Directors' Emoluments | 16,596 | 17.195% | 14,161 | 13,099 | 2,752 | 702 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 149.000 | 50.505% | 99.000 | 83.000 | -- | -- |
| DPS (cts) | 89.000 | -- | 0.000 | -- | -- | -- |
| Dividend Payout Ratio (%) | 59.732% | -- | -- | -- | -- | -- |
| Cash flow per share ($) | 1.687 | -- | 1.325 | 0.710 | -- | -- |
| NBV per share ($) | 4.384 | -- | 2.848 | -- | -- | -- |
| Remarks: | Real time quote last updated: 11/11/2024 08:39 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 983,164 |
| %Change | 47.414% |
| EPS / (LPS) | RMB 0.990 |
| NBV Per Share (¥) | RMB 5.806 |